Last $0.69 USD
Change Today -0.0062 / -0.90%
Volume 86.3K
PTN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

palatin technologies inc (PTN) Snapshot

Open
$0.69
Previous Close
$0.69
Day High
$0.71
Day Low
$0.66
52 Week High
03/20/14 - $1.50
52 Week Low
10/24/13 - $0.57
Market Cap
27.1M
Average Volume 10 Days
153.8K
EPS TTM
$-0.12
Shares Outstanding
39.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PALATIN TECHNOLOGIES INC (PTN)

palatin technologies inc (PTN) Related Bloomberg News

View More Bloomberg News

palatin technologies inc (PTN) Related Businessweek News

No Related Businessweek News Found

palatin technologies inc (PTN) Details

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has completed Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Next Generation Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; and PL-3994, a natriuretic peptide receptor-A agonist that has completed Phase I clinical trial for the treatment of cardiovascular and pulmonary indications, as well as other melanocortin programs. The company has a license, co-development, and commercialization agreement with Gedeon Richter Plc to commercialize Bremelanotide for FSD in Europe and selected countries; and research collaboration and license agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

palatin technologies inc (PTN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $450.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $410.0K
Compensation as of Fiscal Year 2014.

palatin technologies inc (PTN) Key Developments

Palatin Technologies, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014

Palatin Technologies Inc. reported earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported net loss was $4.32 million, or $0.04 loss per share, compared to a net loss of $4.72 million, or $0.04 loss per share, for the same quarter ended June 30, 2013. Loss from operations for the fourth quarter ended June 30, 2014 was $4.32 million, compared to a loss from operations of $4.72 million for the same quarter ended June 30, 2013. Net loss for the year ended June 30, 2014 was $13.93 million, or $0.13 loss per share, compared to a net loss of $20.86 million, or $0.21 loss per share, for the same period ended June 30, 2013. Loss from operations for the year ended June 30, 2014 was $15.79 million, compared to a loss from operations of $15.58 million for the same period ended June 30, 2013.

Palatin Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended June 30, 2014

Palatin Technologies Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended June 30, 2014. For the quarter, the company's loss from operations was $4.3 million compared with $4.7 million a year ago. Loss before income taxes was $4.3 million compared with $4.7 million a year ago. Net loss was $4.3 million or $0.04 per basic and diluted share compared with $4.7 million or $0.04 per basic and diluted share a year ago. The decrease in net loss for the quarter ended June 30, 2014 compared to the net loss for the quarter ended June 30, 2013 was the result of a decrease in operating expenses primarily related to its bremelanotide for female sexual dysfunction program. For the year, the company's loss from operations was $15.8 million compared with $15.6 million a year ago. Loss before income taxes was $15.8 million compared with $22.6 million a year ago. Net loss was $13.9 million or $0.13 per basic and diluted share compared with $20.9 million or $0.21 per basic and diluted share a year ago. The decrease in net loss for the year ended June 30, 2014, compared to the net loss for the year ended June 30, 2013 was mainly attributable to the recognition of a $7.1 million, non-cash charge to expense for the increase in fair value of warrants related to its July 3, 2012 private placement offering.

Palatin Technologies Inc., Q4 2014 Earnings Call, Sep 09, 2014

Palatin Technologies Inc., Q4 2014 Earnings Call, Sep 09, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTN:US $0.69 USD -0.0062

PTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTN.
View Industry Companies
 

Industry Analysis

PTN

Industry Average

Valuation PTN Industry Range
No financial data is available for PTN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PALATIN TECHNOLOGIES INC, please visit www.palatin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.